Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
959.9 USD | -0.47% | -0.47% | +9.29% |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Mar. 18 | US appeals court revives Regeneron's antitrust lawsuit against Novartis | RE |
Evolution of the average Target Price on Regeneron Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Regeneron Pharmaceuticals, Inc.
Morgan Stanley | |
RBC Capital Markets | |
Cantor Fitzgerald | |
UBS | |
Deutsche Bank Securities | |
Truist Securities | |
Barclays | |
Piper Sandler | |
Wells Fargo Securities | |
Goldman Sachs | |
BMO Capital | |
Canaccord Genuity | |
Baird | |
BofA Securities | |
TD Cowen | |
Jefferies & Co. | |
Raymond James | |
WestPark Capital | |
Oppenheimer | |
Guggenheim | |
JPMorgan Chase | |
SVB Securities LLC | |
EF Hutton | |
Cowen | |
Evercore ISI | |
Argus | |
Bernstein | |
Benchmark Capital | |
HC Wainwright | |
SVB Leerink | |
Credit Suisse |
EPS Revisions
- Stock
- Equities
- Stock Regeneron Pharmaceuticals, Inc. - Nasdaq
- Consensus Regeneron Pharmaceuticals, Inc.